| Literature DB >> 22593821 |
Michael Medinger1, Elisabeth Saller, Cornelis L Harteveld, Thomas Lehmann, Lukas Graf, Alicia Rovo, Andreas Buser, Jakob Passweg, André Tichelli.
Abstract
We present a case of a 40-year-old female from Turkey, who was referred to our outpatient clinic for an undetermined thalassemia and sickle cell trait. At first consultation hemoglobin was decreased (71 g/L) with microcytosis (MCV 55.1 fL), and hypochromia (MCHC 239 g/L). The patient had severe iron deficiency. Brilliant cresyl blue staining showed >50% of the erythrocytes with typical Hemoglobin H (HbH) inclusions. High-performance liquid chromatography (HPLC) revealed normal levels of HbA(2) and Hemoglobin F (HbF), and additionally a hemoglobin S (19%). Molecular diagnostics revealed the mutations α2 IVS-I donor site -5nt and a -- MED II deletion in the alpha gene complex and confirmed the heterozygote mutation of the beta-gene at codon 6 (HBB:c.20A>T; HbS). In conclusion, we present an extremely rare combination of HbH disease and sickle cell trait. This combination may explain the mild form of the HbH disease, with moderate anemia, splenomegaly but iron deficiency, rather than iron overload, as usually observed in HbH disease.Entities:
Keywords: HbH disease; alpha-Thalassemia; iron deficiency; sickle cell trait.
Year: 2011 PMID: 22593821 PMCID: PMC3269802 DOI: 10.4081/hr.2011.e30
Source DB: PubMed Journal: Hematol Rep ISSN: 2038-8322
Hematological data from the patient.
| Parameter, Units | At 1st presentation | 3 months after 1500 mg Ferric carboxy-maltose infusion | Reference values |
|---|---|---|---|
| Hb, g/L | 71 | 83 | 120–160 |
| HCT, L/L | 0.30 | 0.33 | 0.36–0.46 |
| MCV, fL | 55.1 | 55.1 | 79–95 |
| MCH, pG | 13.2 | 13.7 | 27.0–33.2 |
| MCHC, g/L | 239 | 250 | 320–360 |
| hypoRBC, % | 76.1 | 69.8 | <5.0 |
| RDW, % | 20.5 | 19.9 | 11.5–14.5 |
| Platelets, ×109/L | 214 | 162 | 150–450 |
| Reticulocytes, ‰ | 20 | 22 | 10–27 |
| Reticulocytes, ×109/L | 108 | 112 | 40–140 |
| WBC, ×109/L | 4.85 | 6.02 | 3.50–10.00 |
| Neutrophils, ×109/L | 3.42 | 4.38 | 1.300–6.700 |
| Ferritin, ng/mL | 7 | 33 | 10–200 |
| Transferrin saturation, % | 7 | 14 | 16–45% |
| sTR, mg/L | 23.11 | 11.64 | 2.2–4.5 |
Hb, hemoglobin; HCT, hematocrit; MCV, mean corpuscolar volume; MCHC, mean corpuscolar hemoglobin concentration; RDW, red cell distribution width; hypoRBC, hypochromic erythrocyte; sTR, soluble transferrin receptor; WBC, white blood cells.
Quantitave values of hemoglobin components from the patient obtained by High-performance liquid chromatography and results of molecular analysis.
| Parameter | Value | References |
|---|---|---|
| Hb A2, % | 2.3 | 2.0–3.5 |
| Hb F,% | 0.7 | <2 |
| Hb H, % | 11 | 0 |
| Abnormal Hb | HbS | None |
| Perc. abnormal Hb, % | 19 | 0 |
| Sickle cell test | Positive | Negative |
| Mutation analysis | 1.α2 IVS-I donor site −5nt / -- MED II deletion | |
| 2. heterozygous Hb S (HBB:c.20A>T) |
Hb, hemoglobin.
Figure 1High-performance liquid chromatography pattern of our patient with Hemoglobin H (HbH) disease. Red graph represents our patient with clear HbH/HbBart's peak at 1.5 minutes and a HbS peak at 11 minutes retention time. Blue graph is a control.
Figure 2Sequence of the alpha 2 gene. Hemizygote deletion of 5 nucleotides at the IVS-I donorsite of the alpha2 gene, HBA2:c.95+2_95+6delTGAGG.